https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-to-launch-leucovorin-calcium-for-injection-usp-350-mg-vial-single-dose-vial/ 2026-01-12T07:38:25+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-establishment-inspection-report-eir-from-u-s-fda-for-its-monroe-facility/ 2026-01-12T07:39:16+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-launch-of-nebzmart-gfb-smartules-and-glenmark-airz-fb-smartules-worlds-first-nebulized-triple-therapy-for-copd/ 2026-01-12T07:39:35+00:00 https://glenmarkpharma.com/press_release/cosmo-and-glenmark-announce-market-authorization-of-winlevi-clascoterone-10-mg-g-cream-for-treatment-of-acne-in-15-countries-in-europe/ 2026-01-12T07:40:07+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-q2fy26-results/ 2026-01-12T07:40:30+00:00 https://glenmarkpharma.com/press_release/glenmark-secures-china-approval-for-ryaltris-reinforcing-respiratory-innovation-leadership/ 2026-01-12T07:41:11+00:00 https://glenmarkpharma.com/press_release/glenmark-secures-exclusive-multi-regional-rights-to-aumolertinib-an-mhra-and-nmpa-approved-third-generation-egfr-tki-from-hansoh-pharma/ 2026-01-12T07:54:46+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-to-launch-8-4-sodium-bicarbonate-injection-usp-50-meq-50-ml-1-meq-ml-single-dose-vial/ 2026-01-12T07:55:16+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-to-launch-ropivacaine-hydrochloride-injection-usp-40-mg-20-ml-2mg-ml-150-mg-30-ml-5-mg-ml-and-200-mg-20-ml-10-mg-ml-single-dose-vials/ 2026-01-12T10:10:37+00:00 https://glenmarkpharma.com/press_release/glenmark-strengthens-oncology-portfolio-with-hengruis-her2-targeting-adc-for-multiple-regions/ 2026-01-12T10:13:32+00:00 https://glenmarkpharma.com/press_release/glenmark-initiates-a-multi-country-phase-3-clinical-trial-for-envafolimab-in-resectable-stage-iii-non-small-cell-lung-cancer/ 2026-01-12T10:15:14+00:00 https://glenmarkpharma.com/press_release/glenmark-to-launch-eribulin-mesylate-injection-1-mg-2-ml-0-5-mg-ml-single-dose-vials/ 2026-01-12T10:18:12+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-to-launch-micafungin-for-injection-usp-50-mg-vial-and-100-mg-vial-single-dose-vial/ 2026-01-12T10:20:33+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-q1fy26-results/ 2026-01-12T10:21:55+00:00 https://glenmarkpharma.com/press_release/ichnos-glenmark-innovation-igi-announces-global-commercialization-strategy-for-isb-2001-following-licensing-deal-with-abbvie/ 2026-01-12T10:23:31+00:00 https://glenmarkpharma.com/press_release/ichnos-glenmark-innovation-igi-and-abbvie-announce-exclusive-global-licensing-agreement-for-isb-2001-a-first-in-class-cd38xbcmaxcd3-trispecific-antibody/ 2026-01-12T10:24:50+00:00 https://glenmarkpharma.com/press_release/glenmark-launches-a-transformative-nutrition-and-livelihood-project-in-emali-kenya/ 2026-01-12T10:26:25+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-launches-tevimbra-in-india/ 2026-01-12T10:28:38+00:00 https://glenmarkpharma.com/press_release/glenmark-therapeutics-inc-usa-launches-olopatadine-hydrochloride-ophthalmic-solution-usp-0-2-otc/ 2026-01-12T10:31:55+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-to-launch-dcgi-approved-brukinsa-in-india-to-advance-treatment-of-hematological-malignancies/ 2026-01-12T10:32:53+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-q4-fy25-financial-results/ 2026-01-12T11:16:46+00:00 https://glenmarkpharma.com/press_release/glenmark-foundation-leads-combat-against-malnutrition-with-its-transformative-initiative-meri-poushtik-rasoi-season-seven/ 2026-01-12T11:17:28+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-to-launch-mixed-amphetamines-immediate-release-tablets/ 2026-01-12T11:18:38+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-launches-vancomycin-hydrochloride-for-injection-usp-750-mg-vial-1-25-g-vial-and-1-5-g-vial-single-dose-vial/ 2026-01-12T11:19:17+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-launches-pioneering-nutrition-program-to-fight-malnutrition-in-the-philippines/ 2026-01-12T11:20:29+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-anda-approval-for-olopatadine-hydrochloride-ophthalmic-solution-usp-0-2-otc/ 2026-01-12T11:21:12+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-expands-cardiometabolic-portfolio-with-the-launch-of-empagliflozin-and-its-fixed-drug-combinations-in-india/ 2026-01-12T11:22:20+00:00 https://glenmarkpharma.com/press_release/glenmark-therapeutics-inc-usa-launches-polyethylene-glycol-3350-powder-for-solution-17-grams-capful-otc/ 2026-01-12T11:23:45+00:00 https://glenmarkpharma.com/press_release/glenmark-nutrition-awards-2025-celebrating-innovation-impact-and-sustainability-in-the-fight-against-malnutrition-in-india/ 2026-01-12T11:24:26+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-launches-acquires-and-launches-acetylcysteine-injection-6-gm-30-ml-200-mg-ml-single-dose-vials/ 2026-01-12T11:25:16+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-launches-epinephrine-injection-usp-10-mg-10-ml-1-mg-ml-multiple-dose-vial/ 2026-01-12T11:29:17+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-consolidated-revenue-growth-of-35-1-ebitda-margin-of-17-7-and-pat-margin-of-10-3-yoy-for-q3-fy2025/ 2026-01-12T11:30:12+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-launches-latanoprost-ophthalmic-solution-0-005/ 2026-01-12T11:31:36+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-launches-clindamycin-phosphate-foam-1/ 2026-01-12T11:32:49+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-launches-phytonadione-injectable-emulsion-usp-10-mg-ml-single-dose-ampules/ 2026-01-12T11:33:51+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-launches-lacosamide-oral-solution-10-mg-ml/ 2026-01-14T04:58:33+00:00 https://glenmarkpharma.com/press_release/ichnos-glenmark-innovation-igi-presents-first-clinical-data-from-phase-1-study-of-trispecific-treat-antibody-isb-2001-in-relapsed-refractory-multiple-myeloma-r-rmm-at-ash-annual-meeting/ 2026-01-14T04:59:55+00:00 https://glenmarkpharma.com/press_release/ichnos-glenmark-innovation-igi-announces-first-presentation-of-data-from-phase-1-study-of-the-trispecific-isb-2001-in-relapsed-refractory-multiple-myeloma-r-rmm-at-upcoming-ash-annual-meeting-2/ 2026-01-14T05:05:42+00:00 https://glenmarkpharma.com/press_release/glenmark-therapeutics-inc-usa-launches-olopatadine-hydrochloride-ophthalmic-solution-usp-0-1-otc/ 2026-01-14T05:07:24+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-consolidated-revenue-growth-of-6-9-ebitda-margin-of-18-1-and-pat-margin-of-10-5-yoy-for-q1-fy-2024-25/ 2026-01-14T05:08:19+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-anda-approval-for-esomeprazole-magnesium-delayed-release-capsules-usp-20-mg-otc/ 2026-01-14T05:10:49+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-q4-fy2023-24-financial-results/ 2026-01-14T05:14:17+00:00 https://glenmarkpharma.com/press_release/glenmark-and-beigene-enter-into-an-agreement-for-marketing-and-distribution-of-tislelizumab-and-zanubrutinib-in-india/ 2026-01-14T05:17:26+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-brimonidine-tartrate-and-timolol-maleate-ophthalmic-solution-0-20-5/ 2026-01-14T05:18:08+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-ltd-reports-consolidated-revenue-of-rs-29096-mn-for-q3-fy-2023-24/ 2026-01-14T05:23:41+00:00 https://glenmarkpharma.com/press_release/glenmark-partners-with-pfizer-to-launch-abrocitinib-in-india/ 2026-01-14T05:24:54+00:00 https://glenmarkpharma.com/press_release/glenmark-and-ichnos-take-a-collaborative-leap-to-accelerate-innovation-in-cancer-treatment-with-their-alliance-%e2%80%90-ichnos-glenmark-innovation/ 2026-01-14T05:25:31+00:00 https://glenmarkpharma.com/press_release/glenmark-jiangsu-alphamab-biopharmaceuticals-and-3d-medicines-announce-the-signing-of-a-license-agreement-for-kn035-envafolimab-for-multiple-geographies-around-the-world/ 2026-01-14T05:26:07+00:00 https://glenmarkpharma.com/press_release/glenmark-is-the-first-to-launch-biosimilar-of-popular-anti-diabetic-drug-liraglutide-in-india/ 2026-01-14T05:26:45+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-launches-travoprost-ophthalmic-solution-usp-0-004-ionic-buffered-solution/ 2026-01-14T05:35:25+00:00 https://glenmarkpharma.com/press_release/ichnos-glenmark-innovation-igi-announces-first-presentation-of-data-from-phase-1-study-of-the-trispecific-isb-2001-in-relapsed-refractory-multiple-myeloma-r-rmm-at-upcoming-ash-annual-meeting/ 2026-01-14T05:37:55+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-topiramate-capsules-usp-15-mg-and-25-mg/ 2026-01-14T05:40:31+00:00 https://glenmarkpharma.com/press_release/gpl_pdfs-media-press-release_glenmark-receives-anda-approval-for-brimonidine-tartrate-and-timolol-maleate-ophthalmic-solution-0-2_0-5-pdf/ 2026-01-14T05:42:51+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-consolidated-revenue-growth-of-6-3-and-adjusted-ebitda-growth-of-8-3-yoy-for-q2-fy-2023-24/ 2026-01-14T05:48:13+00:00 https://glenmarkpharma.com/press_release/62017/ 2026-01-14T05:52:08+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-is-first-to-launch-a-triple-drug-fdc-of-teneligliptin-dapagliflozin-metformin-in-india-for-type-2-diabetes-in-adults-with-co-morbidities/ 2026-01-14T07:11:15+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-apremilast-tablets-10-mg-20-mg-and-30-mg/ 2026-01-14T07:13:26+00:00 https://glenmarkpharma.com/press_release/cosmo-and-glenmark-announce-the-signing-of-distribution-and-license-agreements-for-winlevi-in-europe-and-south-africa/ 2026-01-14T07:15:16+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-announces-proposed-divestment-of-majority-stake-in-glenmark-life-sciences/ 2026-01-14T07:16:49+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-sanda-approval-for-tacrolimus-ointment-0-03/ 2026-01-14T07:18:05+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-saxagliptin-tablets-2-5-mg-and-5-mg/ 2026-01-14T07:20:10+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-revenue-growth-of-11-7-yoy-q4-5-6-for-the-full-year-fy-2022-23/ 2026-01-14T07:21:00+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-is-great-place-to-work-certified-in-india/ 2026-01-14T07:21:57+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-calcipotriene-and-betamethasone-dipropionate-foam-0-0050-064/ 2026-01-14T07:22:58+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-prochlorperazine-maleate-tablets-usp-5-mg-and-10-mg/ 2026-01-14T07:24:02+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-acceptance-from-u-s-fda-on-its-ind-application-for-grc-54276-to-proceed-with-a-phase-1-2-first-in-human-clinical-study-of-the-molecule-for-the-treatment-of-patients-with-advanced-s/ 2026-01-14T07:25:32+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-clindamycin-hydrochloride-capsules-usp-75-mg-150-mg-and-300-mg/ 2026-01-14T07:26:45+00:00 https://glenmarkpharma.com/press_release/glenmark-and-cediprof-announce-exclusive-distribution-agreement-in-the-united-states-for-u-s-fda-approved-dextroamphetamine-saccharate-amphetamine-aspartate-dextroamphetamine-sulfate-and-amphetamin/ 2026-01-14T07:28:03+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-2nd-anda-tentative-approval-for-saxagliptin-tablets-2-5-mg-and-5-mg/ 2026-01-14T07:29:27+00:00 https://glenmarkpharma.com/press_release/the-glenmark-nutrition-awards-2023-recognized-ngos-and-institutions-tackling-malnutrition-in-mothers-and-children/ 2026-01-14T07:32:39+00:00 https://glenmarkpharma.com/press_release/glenmark-launches-akynzeo-i-v-in-india-first-fixed-i-v-antiemetic-combination-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting/ 2026-01-14T07:33:48+00:00 https://glenmarkpharma.com/press_release/heart-failure-treatment-becomes-more-affordable-with-glenmark-launching-the-sacubitril-valsartan-tablets-in-india/ 2026-01-14T07:34:29+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-launches-bumetanide-injection-usp-1-mg-4-ml-0-25-mg-ml-single-dose-vials-and-2-5-mg-10-ml-0-25-mg-ml-multi-dose-vials/ 2026-01-14T07:35:20+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-revenue-growth-of-22-5-ebitda-growth-of-46-2-yoy-for-q1-fy-2023-24/ 2026-01-27T09:58:30+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-revenue-growth-of-9-2-and-pat-growth-of-21-3-yoy-for-q3-fy-2022-23/ 2026-01-27T09:58:51+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-nicardipine-hydrochloride-capsules-20-mg-and-30-mg/ 2026-01-30T08:17:07+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-launches-epinephrine-injection-usp-30-mg-30-ml-1-mg-ml-multiple-dose-vial/ 2026-01-30T10:17:02+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-sodium-phenylbutyrate-tablets-usp-500-mg/ 2026-01-30T11:08:00+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-revenue-growth-of-7-2-yoy-and-ebitda-margin-of-18-4-for-q2-fy-2022-23/ 2026-01-30T11:09:01+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-reaches-settlement-agreement-with-pfizer-for-axitinib-tablets-1-mg-and-5-mg/ 2026-01-30T11:09:54+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-continues-to-expand-its-over-the-counter-otc-portfolio-with-the-acquisition-of-approved-andas-from-wockhardt-limited/ 2026-01-30T11:10:49+00:00 https://glenmarkpharma.com/press_release/glenmark-launches-sitagliptin-and-its-fixed-dose-combinations-at-affordable-price-for-adults-with-type-2-diabetes-in-india/ 2026-01-30T11:11:05+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-launches-minym-gel-indias-first-topical-minocycline-4-gel-for-the-treatment-of-moderate-to-severe-acne/ 2026-01-30T11:11:53+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-and-sanotize-announce-peer-reviewed-publication-of-its-phase-3-clinical-trials-on-sanotizes-novel-nitric-oxide-nasal-spray-for-covid-19-in-lancet-journal/ 2026-01-30T11:12:18+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-norethindrone-acetate-and-ethinyl-estradiol-capsules-and-ferrous-fumarate-capsules1-mg-20-mcg/ 2026-01-30T11:12:31+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-revenue-of-inr-27773-mn-and-pat-of-inr-2111-mn-for-q1-fy-2022-23/ 2026-01-30T11:13:06+00:00 https://glenmarkpharma.com/press_release/hikma-launches-ryaltris-seasonal-allergic-rhinitis-nasal-spray-in-the-us/ 2026-01-30T11:13:20+00:00 https://glenmarkpharma.com/press_release/bausch-health-and-glenmark-announce-the-approval-of-ryaltris-in-canada/ 2026-01-30T11:13:37+00:00 https://glenmarkpharma.com/press_release/glenmark-becomes-the-first-pharmaceutical-company-to-launch-lobeglitazone-in-india-for-uncontrolled-type-2-diabetes-in-adults/ 2026-01-30T11:13:59+00:00 https://glenmarkpharma.com/press_release/glenmark-is-the-first-company-to-launch-in-india-a-triple-fdc-of-teneligliptin-pioglitazone-metformin-for-adults-with-type-2-diabetes-high-insulin-resistance/ 2026-01-30T11:14:25+00:00 https://glenmarkpharma.com/press_release/glenmark-becomes-the-first-company-in-india-to-launch-teneligliptin-dapagliflozin-fixed-dose-combination-for-adults-with-type-2-diabetes-having-comorbidities/ 2026-01-30T11:14:40+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-launches-fingolimod-capsules-0-5-mg-in-the-us/ 2026-01-30T11:14:57+00:00 https://glenmarkpharma.com/press_release/glenmark-becomes-the-first-pharmaceutical-company-to-launch-indacaterol-mometasone-fixed-dose-combination-drug-for-asthma-in-india/ 2026-02-02T09:44:40+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-revenue-growth-of-5-6-yoy-q4-12-4-for-the-full-year-fy-2021-22/ 2026-02-02T09:46:10+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-sanda-approval-for-abiraterone-acetate-tablets-usp-500-mg/ 2026-02-02T09:47:19+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-tentative-anda-approval-for-calcipotriene-and-betamethasone-dipropionate-foam-0-0050-064/ 2026-02-02T09:48:26+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-the-india-pharma-innovation-of-the-year-award-from-the-government-of-india/ 2026-02-02T09:49:36+00:00 https://glenmarkpharma.com/press_release/glenmark-becomes-the-first-pharmaceutical-company-to-launch-teneligliptin-pioglitazone-fixed-dose-combination-drug-for-type-2-diabetes-in-india/ 2026-02-02T09:51:02+00:00 https://glenmarkpharma.com/press_release/glenmark-specialty-s-a-receives-approval-for-conducting-phase-1-clinical-trial-of-its-novel-molecule-grc-54276-in-patients-with-advanced-solid-tumors-and-hodgkins-lymphoma/ 2026-02-02T09:52:29+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-anda-approval-for-lacosamide-tablets-usp-50-mg-100-mg-150-mg-and-200-mg/ 2026-02-02T09:53:45+00:00 https://glenmarkpharma.com/press_release/glenmark-inks-agreement-with-astrazeneca-to-commercialize-its-product-pulmicort-respules-in-columbia/ 2026-02-02T09:55:00+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-revenue-growth-of-13-9-and-ebitda-growth-of-30-8-yoy-for-q3-fy-2021-22/ 2026-02-02T09:57:15+00:00 https://glenmarkpharma.com/press_release/glenmark-launches-nitric-oxide-nasal-spray-fabispray-in-india-for-the-treatment-of-adult-patients-with-covid-19-in-partnership-with-sanotize/ 2026-02-02T09:58:16+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-metronidazole-vaginal-gel-0-75/ 2026-02-02T09:59:28+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-bisoprolol-fumarate-and-hydrochlorothiazide-tablets-usp-2-5-mg-6-25-mg-5-mg-6-25-mg-and-10-mg-6-25-mg/ 2026-02-02T10:00:35+00:00 https://glenmarkpharma.com/press_release/glenmark-specialty-s-a-and-lotus-international-pte-ltd-enter-into-exclusive-licensing-agreement-for-commercializing-ryaltris-nasal-spray-in-singapore-hong-kong-and-vietnam/ 2026-02-02T10:01:29+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-tentative-approval-for-regadenoson-injection-0-4-mg-5-ml-0-08-mg-ml-single-dose-pre-filled-syringe/ 2026-02-02T10:02:50+00:00 https://glenmarkpharma.com/press_release/glenmark-specialty-s-a-switzerland-receives-nda-approval-by-the-united-states-food-and-drug-administration-fda-for-ryaltris-nasal-spray-for-the-treatment-of-symptoms-of-seasonal-allergic/ 2026-02-02T10:03:57+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-makes-it-to-the-prestigious-dow-jones-sustainability-emerging-markets-index-for-the-fourth-consecutive-year/ 2026-02-05T08:30:56+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-revenue-growth-of-6-6-and-pat-growth-of-10-1-yoy-for-q2-fy-2021-22/ 2026-02-05T08:32:21+00:00 https://glenmarkpharma.com/press_release/glenmark-becomes-the-first-company-to-launch-remogliflozin-vildagliptin-metformin-fixed-dose-combination-at-an-affordable-price-for-adults-with-type-2-diabetes-in-india/ 2026-02-05T08:33:19+00:00 https://glenmarkpharma.com/press_release/glenmark-launches-tavulus-for-copd-treatment-in-spain-becoming-one-of-the-first-companies-to-launch-a-bioequivalent-version-of-the-dry-powder-inhaler/ 2026-02-05T08:34:20+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-marketing-approval-for-ryaltris-an-innovative-combination-nasal-spray-in-13-countries-across-the-eu-and-uk/ 2026-02-05T08:35:15+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-clindamycin-phosphate-foam-1/ 2026-02-05T08:36:10+00:00 https://glenmarkpharma.com/press_release/glenmark-concludes-post-marketing-surveillance-pms-study-on-favipiravir-fabiflu-in-1000-covid-19-patients-findings-reinforce-the-drugs-safety-and-efficacy-in-real-world-settings/ 2026-02-05T08:36:57+00:00 https://glenmarkpharma.com/press_release/glenmark-pharma-reports-revenue-growth-of-26-and-pat-growth-of-21-yoy-for-q1-fy-2021-22/ 2026-02-05T08:37:46+00:00 https://glenmarkpharma.com/press_release/glenmark-inks-agreement-with-canadian-biotech-sanotize-to-commercialize-nitric-oxide-nasal-spray-for-covid-19-treatment-in-india-and-other-asian-markets/ 2026-02-05T08:39:33+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-anda-tentative-approval-for-nintedanib-capsules-100-mg-and-150-mg/ 2026-02-05T08:45:16+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-arformoterol-tartrate-inhalation-solution-15-mcg-2-ml-unit-dose-vials/ 2026-02-05T08:46:09+00:00 https://glenmarkpharma.com/press_release/glenmark-launches-tiogiva-becoming-one-of-the-first-companies-in-the-uk-to-launch-a-bioequivalent-version-of-tiotropium-bromide-dry-powder-inhaler/ 2026-02-05T08:47:01+00:00 https://glenmarkpharma.com/press_release/glenmark-releases-interim-data-from-pms-study-on-favipiravir/ 2026-02-05T08:47:49+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-theophylline-extended-release-tablets-300-mg-and-450-mg-granted-competitive-generic-therapy-cgt-designation-and-is-eligible-for-180-days-of-cgt/ 2026-02-05T08:48:47+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-launches-rufinamide-tablets-usp-200-mg-and-400-mg/ 2026-02-05T08:49:47+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-revenues-grow-2-8-to-rs-109439-mn-in-fy21/ 2026-02-05T08:53:51+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-icatibant-injection-30-mg-3-ml-10-mg-ml-single-dose-prefilled-syringe/ 2026-02-05T08:54:42+00:00 https://glenmarkpharma.com/press_release/glenmark-launches-ryaltris-az-at-an-affordable-price-in-india/ 2026-02-05T08:55:32+00:00 https://glenmarkpharma.com/press_release/glenmarks-ryaltris-nasal-spray-now-approved-in-europe-for-the-first-line-treatment-of-allergic-rhinitis-in-patients-over-12-years-of-age/ 2026-02-05T08:56:19+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-chlorpromazine-hydrochloride-tablets-usp-10-mg-25-mg-50-mg-100-mg-and-200-mg-granted-competitive-generic-therapy-cgt-designation-and-is-elig/ 2026-02-05T08:57:05+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-diltiazem-hydrochloride-extended-release-capsules-usp-60-mg-90-mg-and-120-mg-granted-competitive-generic-therapy-cgt-designation-and-is-eligib/ 2026-02-05T08:57:48+00:00 https://glenmarkpharma.com/press_release/glenmark-and-bausch-health-join-together-to-commercialize-ryaltris-nasal-spray-in-canada/ 2026-02-05T08:58:41+00:00 https://glenmarkpharma.com/press_release/glenmark-signs-on-rohit-sharma-as-brand-ambassador-of-candid-powder/ 2026-02-05T08:59:34+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-india-pharma-innovation-of-the-year-award-from-the-govt-of-india/ 2026-02-05T09:00:22+00:00 https://glenmarkpharma.com/press_release/glenmarks-ryaltris-innovative-single-nasal-spray-ready-to-market-in-russia/ 2026-02-05T09:01:11+00:00 https://glenmarkpharma.com/press_release/glenmark-launches-sutib-sunitinib-priced-96-lower-than-the-innovator-brand-reduces-the-risk-of-kidney-cancer-progression-by-58/ 2026-02-05T09:02:03+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-sales-rises-by-3-88-to-rs-27605-07-mn-in-q3-fy-2020-21/ 2026-02-05T09:02:42+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-clindamycin-phosphate-gel-usp-1/ 2026-02-05T09:03:27+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-topiramate-extended-release-capsules-25-mg-50-mg-100-mg-150-mg-and-200-mg/ 2026-02-05T09:04:13+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-amphetamine-sulfate-tablets-usp-5-mg-and-10-mg/ 2026-02-05T09:04:52+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-anda-approval-for-dimethyl-fumarate-delayed-release-capsules-120-mg-and-240-mg/ 2026-02-13T07:48:38+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-sirolimus-tablets-0-5-mg-1-mg-and-2-mg/ 2026-02-13T07:49:40+00:00 https://glenmarkpharma.com/press_release/glenmark-announces-results-of-its-faith-combination-trial/ 2026-02-13T07:50:42+00:00 https://glenmarkpharma.com/press_release/glenmark-introduces-nindanib-nintedanib-for-the-treatment-of-pulmonary-fibrosis-in-india/ 2026-02-13T07:51:09+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-revenue-increased-by-4-88-to-rs-29524-79-mn-for-q2-fy-2020-21/ 2026-02-13T09:50:59+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-tacrolimus-capsules-usp-0-5-mg-1-mg-and-5-mg/ 2026-02-13T09:51:16+00:00 https://glenmarkpharma.com/press_release/recently-published-data-on-favipiravir-as-treatment-for-mild-to-moderate-covid-19-demonstrates-significant-improvement-in-time-to-clinical-cure/ 2026-02-13T09:51:25+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-secures-its-position-in-the-prestigious-dow-jones-sustainability-emerging-markets-index-for-the-third-year-in-a-row/ 2026-02-13T09:51:37+00:00 https://glenmarkpharma.com/press_release/glenmark-to-divest-select-anti-allergy-brands-to-dr-reddys-in-russia-ukraine-kazakhstan-and-uzbekistan-in-anticipation-of-its-ryaltris-launch/ 2026-02-13T09:51:47+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-final-approval-for-tadalafil-tablets-2-5-mg-5-mg-10-mg-and-20-mg-and-receives-anda-tentative-approvals-for-gabapentin-enacarbil-extended-release-tablets-300/ 2026-02-13T09:52:55+00:00 https://glenmarkpharma.com/press_release/glenmark-becomes-the-first-company-to-launch-remogliflozin-vildagliptin-fixed-dose-combination-at-an-affordable-price-for-adults-with-type-2-diabetes-in-india/ 2026-02-13T09:53:02+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-and-menarini-enter-into-exclusive-licensing-agreement-for-commercializing-ryaltris-nasal-spray-across-numerous-markets-throughout-europe/ 2026-02-13T09:53:09+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-tentative-approval-for-dabigatran-etexilate-capsules-75-mg-110-mg-and-150-mg/ 2026-02-13T09:53:16+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-tentative-approval-for-axitinib-tablets1-mg-and-5-mg/ 2026-02-13T09:53:22+00:00 https://glenmarkpharma.com/press_release/glenmark-appoints-dipankar-bhattacharjee-to-its-board-of-directors/ 2026-02-13T09:55:05+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-revenue-grew-by-0-94-at-rs-23447-87-mn-for-q1-fy-2020-21/ 2026-02-13T09:57:13+00:00 https://glenmarkpharma.com/press_release/glenmark-introduces-higher-strength-400-mg-of-fabiflu-to-reduce-pill-burden-of-covid-19-treatment/ 2026-02-13T09:57:59+00:00 https://glenmarkpharma.com/press_release/glenmark-announces-top-line-results-from-phase-3-clinical-trial-of-favipiravir-in-patients-with-mild-to-moderate-covid-19/ 2026-02-13T09:59:26+00:00 https://glenmarkpharma.com/press_release/glenmark-launches-worlds-first-hypertension-awareness-symbol-endorsed-by-association-of-physicians-of-india-api-hypertension-society-of-india-hsi/ 2026-02-13T10:00:25+00:00 https://glenmarkpharma.com/press_release/glenmark-commences-1000-patients-post-marketing-surveillance-study-with-covid-19-who-are-administered-fabiflu/ 2026-02-13T10:01:19+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-revenue-rises-7-96-to-rs-27674-89-mn-for-q4-fy2019-20/ 2026-02-13T10:02:32+00:00 https://glenmarkpharma.com/press_release/glenmark-introduces-favipiravir-fabiflu-for-the-treatment-of-mild-to-moderate-covid-19-in-india/ 2026-02-13T10:03:13+00:00 https://glenmarkpharma.com/press_release/glenmark-becomes-the-first-pharmaceutical-company-in-india-to-receive-regulatory-approval-for-oral-antiviral-favipiravir-for-the-treatment-of-mild-to-moderate-covid-19/ 2026-02-13T10:03:57+00:00 https://glenmarkpharma.com/press_release/indian-regulator-approves-favipiravir-for-the-treatment-of-mild-to-moderate-covid-19-in-india/ 2026-02-13T10:04:52+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-fingolimod-capsules-0-5-mg/ 2026-02-13T10:05:31+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-chlorzoxazone-tablets-usp-375-mg-and-750-mg-glenmarks-first-anda-approval-out-of-their-new-u-s-facility/ 2026-02-13T10:09:32+00:00 https://glenmarkpharma.com/press_release/glenmark-to-commence-another-new-phase-3-clinical-trial-on-a-combination-of-two-anti-viral-drugs-favipiravir-and-umifenovir-in-hospitalized-patients-of-moderate-covid-19-in-india/ 2026-02-13T10:10:07+00:00 https://glenmarkpharma.com/press_release/glenmark-initiates-phase-3-clinical-trials-on-antiviral-favipiravir-for-covid-19-patients-in-india/ 2026-02-13T10:10:46+00:00 https://glenmarkpharma.com/press_release/glenmark-introduces-3-in-1-inhaler-therapy-for-copd-in-india-promising-reduction-in-risk-of-severe-attacks-and-improvement-in-lung-function/ 2026-02-13T10:11:25+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-approval-from-the-regulator-dcgi-to-conduct-clinical-trials-in-india-on-favipiravir-antiviral-tablets-for-covid-19-patients/ 2026-02-13T10:12:36+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-tentative-approval-for-dapagliflozin-and-saxagliptin-tablets-10-mg-5-mg/ 2026-02-13T10:14:07+00:00 https://glenmarkpharma.com/press_release/glenmark-pledges-50-lakh-meals-for-undernourished-children-pregnant-women-and-daily-wage-earners-amidst-covid-19-pandemic/ 2026-02-13T10:15:04+00:00 https://glenmarkpharma.com/press_release/glenmark-divests-vwash-a-female-intimate-hygiene-wash-to-hindustan-unilever/ 2026-02-13T10:15:55+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-tentative-approval-for-dapagliflozin-tablets-5-mg-and-10-mg/ 2026-02-13T10:16:44+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-and-hikma-enter-into-an-exclusive-licensing-agreement-for-commercializing-ryaltris-seasonal-allergic-rhinitis-nasal-spray-in-the-us/ 2026-02-13T10:17:31+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-revenue-rises-by-7-07-to-rs-27355-61-mn-in-q3-fy-2019-20/ 2026-02-13T10:18:06+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-deferasirox-tablets-for-oral-suspension-125-mg-250-mg-and-500-mg/ 2026-02-13T10:19:03+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-anda-approval-for-metformin-hydrochloride-extended-release-tablets-usp-500-mg-and-1000-mg/ 2026-02-17T09:53:52+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-product-approval-for-ryaltrisr-in-australia/ 2026-02-17T09:54:56+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-revenue-rises-9-05-to-rs-28150-4-mn-in-q2-fy-2019-20/ 2026-02-17T09:55:55+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-adapalene-and-benzoyl-peroxide-gel-0-12-5/ 2026-02-17T09:57:49+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-abiraterone-acetate-tablets-usp-250-mg/ 2026-02-17T10:00:37+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-tentative-anda-approval-for-dimethyl-fumarate-delayed-release-capsules-120-mg-and-240-mg/ 2026-02-17T10:01:44+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-approval-from-russian-ministry-of-healthcare-to-market-montlezir-levocetirizinemontelukast-film-coated-tablets/ 2026-02-17T10:02:30+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-secures-its-position-in-the-prestigious-dow-jones-sustainability-emerging-markets-index-for-the-second-year-in-a-row/ 2026-02-17T10:03:16+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-orphan-drug-designation-for-gbr-1342-a-bispecific-antibody-candidate-under-evaluation-for-the-treatment-of-multiple-myeloma/ 2026-02-17T10:05:02+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-clobetasol-propionate-foam-0-05/ 2026-02-17T10:19:20+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-pimecrolimus-cream-1/ 2026-02-17T10:20:21+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-fulvestrant-injection-250-mg-5-ml-50-mg-ml/ 2026-02-17T10:21:01+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-approval-for-combination-of-remogliflozin-etabonate-and-metformin-hydrochloride-for-adults-with-type-2-diabetes-in-india/ 2026-02-17T10:22:49+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-revenue-at-rs-23228-79-mn-for-q1-fy-2019-20/ 2026-02-17T10:23:31+00:00 https://glenmarkpharma.com/press_release/glenmark-torrent-sign-licensing-agreement-for-co-marketing-of-remogliflozin-etabonate-in-india-2/ 2026-02-17T10:25:54+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-ranolazine-extended-release-tablets-500-mg-and-1000-mg/ 2026-02-17T10:26:47+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-ezetimibe-and-simvastatin-tablets-10-mg-10-mg-10-mg-20-mg-10-mg-40-mg-and-10-mg-80-mg/ 2026-02-18T06:57:50+00:00 https://glenmarkpharma.com/press_release/glenmark-to-partner-with-novartis-to-promote-commercialize-and-distribute-three-respiratory-products-in-brazil/ 2026-02-18T06:59:10+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-tentative-anda-approval-for-clindamycin-phosphate-foam-1/ 2026-02-18T07:00:00+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-revenue-rises-12-44-to-rs-25634-74-mn-for-q4-fy-2018-19/ 2026-02-18T07:04:32+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-aspirin-and-extended-release-dipyridamole-capsules-25-mg-200-mg/ 2026-02-18T07:05:33+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-solifenacin-succinate-tablets-5-mg-and-10-mg/ 2026-02-18T07:06:28+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-esomeprazole-magnesium-delayed-release-capsules-usp-20-mg-and-40-mg/ 2026-02-18T07:07:24+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-results-from-a-phase-3-study-of-ryaltris-an-investigational-product-for-the-treatment-of-seasonal-allergic-rhinitis-in-patients-aged-6-to-under-12-years/ 2026-02-18T07:08:40+00:00 https://glenmarkpharma.com/press_release/glenmark-appoints-dr-yasir-rawjee-as-chief-executive-officer-of-glenmark-life-sciences-its-subsidiary-for-the-api-business/ 2026-02-18T07:11:23+00:00 https://glenmarkpharma.com/press_release/glenmark-therapeutics-expands-specialty-portfolio-with-otiprio-co-promotion-agreement-in-the-u-s-with-otonomy-for-acute-otitis-externa-indication/ 2026-02-18T07:15:05+00:00 https://glenmarkpharma.com/press_release/glenmark-launches-novel-globally-researched-anti-diabetes-drug-remogliflozin-in-india/ 2026-02-18T07:48:42+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-approval-from-russian-ministry-of-healthcare-to-market-momate-rhino-metered-nasal-spray-as-an-over-the-counter-otc-product/ 2026-02-18T07:49:22+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-clindamycin-and-benzoyl-peroxide-gel-15/ 2026-02-18T07:50:20+00:00 https://glenmarkpharma.com/press_release/glenmark-announces-appointment-of-alessandro-riva-as-ceo-of-its-new-innovation-company/ 2026-02-18T07:51:01+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-anda-approval-for-telmisartan-and-hydrochlorothiazide-tablets-usp/ 2026-02-18T07:51:58+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-presentation-of-new-subtype-analysis-of-gbr-830-an-investigational-anti-ox40-monoclonal-antibody-at-the-american-academy-of-dermatology-annual-meeting/ 2026-02-18T07:52:35+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-results-from-new-analysis-of-pooled-data-on-ryaltris-an-investigational-product-for-the-treatment-of-seasonal-allergic-rhinitis-at-aaaai-2019-annual-meeti/ 2026-02-18T10:02:53+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-to-present-new-analysis-of-pooled-data-on-ryaltris-an-investigational-product-for-the-treatment-of-seasonal-allergic-rhinitis-at-the-aaaai-2019-annual-meeting/ 2026-02-18T10:04:06+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-anda-approval-for-clobetasol-propionate-foam-0-05/ 2026-02-18T10:05:03+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-revenue-rises-15-95-to-rs-25550-45-mn-in-q3-fy-2018-19/ 2026-02-18T10:06:28+00:00 https://glenmarkpharma.com/press_release/glenmark-to-spin-off-its-innovation-business-into-a-new-company-in-the-us/ 2026-02-18T10:07:57+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-sevelamer-hydrochloride-tablets-400-mg-and-800-mg/ 2026-02-18T10:10:24+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-tentative-anda-approval-for-fulvestrant-injection-250-mg-5-ml-50-mg-ml/ 2026-02-18T10:11:08+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-enters-into-an-exclusive-license-agreement-with-grandpharma-china-co-ltd-for-commercializing-investigational-seasonal-allergic-rhinitis-nasal-spray-ryaltris-in-china/ 2026-02-18T10:11:49+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-tentative-anda-approval-for-topiramate-extended-release-capsules/ 2026-02-18T10:13:09+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-tentative-anda-approval-for-abiraterone-acetate-tablets-usp-250-mg/ 2026-02-18T10:13:51+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-enters-into-an-exclusive-licensing-agreement-with-yuhan-corporation-for-commercializing-investigational-seasonal-allergic-rhinitis-nasal-spray-ryaltris-in-south-korea/ 2026-02-18T10:14:35+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-entry-into-branded-dermatology-segment-in-the-united-states/ 2026-02-23T11:03:15+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-fluocinolone-acetonide-oil-0-01-ear-drops/ 2026-02-23T11:04:10+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-new-data-on-gbr-1302-a-her2xcd3-bispecific-antibody-presented-at-the-esmo-immuno-oncology-congress-2018/ 2026-02-23T11:04:56+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-hydrocortisone-valerate-ointment-usp-0-2/ 2026-02-23T11:05:45+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-atovaquone-oral-suspension-usp-750-mg-5-ml/ 2026-02-23T11:09:59+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-tentative-anda-approval-for-clobetasol-propionate-foam-0-05-emulsion-formulation/ 2026-02-23T11:11:52+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-azelaic-acid-gel-15/ 2026-02-23T11:13:01+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-new-data-presentations-on-ryaltris-at-the-acaai-annual-scientific-meeting-2018/ 2026-02-23T11:13:47+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-anda-approval-for-teriflunomide-tablets-7-mg-and-14-mg/ 2026-02-23T11:18:00+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-revenue-rises-14-39-to-rs-25813-32-mn-in-q2-fy-2018-19/ 2026-02-23T11:18:59+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-decision-to-launch-phase-1-trial-in-solid-tumors-for-its-cd38xcd3-bispecific-antibody-gbr-1342-based-on-human-translational-data/ 2026-02-23T11:20:14+00:00 https://glenmarkpharma.com/press_release/glenmark-launches-globally-renowned-hair-growth-formula-nourkrin-in-russia/ 2026-02-23T11:21:06+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-fluocinolone-acetonide-topical-oil-0-01-scalp-oil/ 2026-02-24T07:28:28+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-fluocinolone-acetonide-topical-oil-0-01-body-oil/ 2026-02-24T07:44:56+00:00 https://glenmarkpharma.com/press_release/data-on-glenmarks-gbr-830-first-in-class-investigational-anti-ox40-monoclonal-antibody-in-development-for-treatment-of-atopic-dermatitis-to-be-presented-at-the-fall-clinical-dermatology-c/ 2026-02-24T07:45:39+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-hydrocortisone-valerate-cream-usp-0-2/ 2026-02-24T07:46:26+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inducted-into-the-dow-jones-sustainability-indices-djsi-emerging-markets-2018-one-of-the-most-prestigious-global-sustainability-benchmarks/ 2026-02-24T09:28:26+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-estradiol-vaginal-inserts-usp-10-mcg/ 2026-02-24T09:29:05+00:00 https://glenmarkpharma.com/press_release/glenmark-secures-marketing-authorization-in-germany-for-its-generic-version-of-seretide-accuhaler/ 2026-02-24T09:29:56+00:00 https://glenmarkpharma.com/press_release/glenmark-enters-into-an-exclusive-licensing-agreement-to-commercialize-generic-tiotropium-bromide-dry-powder-inhaler-in-western-europe/ 2026-02-24T09:31:19+00:00 https://glenmarkpharma.com/press_release/glenmark-enters-into-a-collaboration-with-true-north-for-its-orthopaedic-and-pain-management-business-in-india/ 2026-02-24T09:32:18+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-revenue-at-rs-21656-17-mn-for-q1-fy-2018-19/ 2026-02-24T09:33:09+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-fda-acceptance-of-the-companys-first-new-drug-application-for-ryaltris-for-patients-with-seasonal-allergic-rhinitis/ 2026-02-24T09:34:07+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-partner-elite-pharmaceuticals-receives-us-fda-approval-for-generic-methadone-hydrochloride-tablets/ 2026-02-24T09:35:00+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-and-harbour-biomed-sign-agreement-for-greater-china-to-develop-gbr-1302-a-first-in-class-bispecific-antibody-for-treatment-of-her2-positive-cancers/ 2026-02-24T09:35:48+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-encouraging-phase-1-results-supporting-biosimilarity-criteria-for-gbr-310-compared-to-the-reference-product-omalizumab/ 2026-02-24T09:38:17+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-colesevelam-hydrochloride-for-oral-suspension-1-875-grams-packet-and-3-75-grams-packet/ 2026-02-24T09:38:57+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-expands-its-oncology-franchise-in-india-with-the-launch-of-helsinns-akynzeo-a-combination-drug-for-the-prevention-of-cinv-chemotherapy-induced-nausea-and-vomi/ 2026-02-24T09:39:43+00:00 https://glenmarkpharma.com/press_release/glenmark-announces-exclusive-licensing-agreement-with-seqirus-for-its-investigational-seasonal-allergic-rhinitis-nasal-spray-ryaltris-for-australia-and-new-zealand-markets/ 2026-02-24T09:40:27+00:00 https://glenmarkpharma.com/press_release/the-us-fda-approves-first-supplemental-abbreviated-new-drug-application-sanda-for-glenmark-pharmaceuticals-manufacturing-facility-in-monroe-north-carolina/ 2026-02-24T09:41:34+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-hailey-1-5-30-and-hailey-fe-1-5-30/ 2026-02-24T09:42:18+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-revenue-at-rs-22798-16-mn-for-q4-fy-2017-18/ 2026-02-24T09:43:05+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-poster-presentations-on-gbr-1302-and-gbr-1342-her2xcd3-and-cd38xcd3-bispecific-antibodies-at-the-2018-asco-annual-meeting/ 2026-02-24T09:43:49+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-the-companys-first-new-drug-application-submission-for-ryaltristm-for-patients-with-seasonal-allergic-rhinitis/ 2026-02-24T09:48:09+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-colesevelam-hydrochloride-tablets-625-mg/ 2026-02-24T09:48:46+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-oral-presentation-of-new-data-on-gbr-830-an-investigational-anti-ox40-monoclonal-antibody-at-the-international-investigative-dermatology-meeting/ 2026-02-24T09:49:28+00:00 https://glenmarkpharma.com/press_release/glenmark-announces-grant-of-substitution-and-successful-launch-of-generic-seretide-accuhaler-in-denmark/ 2026-02-24T09:50:20+00:00 https://glenmarkpharma.com/press_release/new-and-updated-data-on-glenmark-pharmaceuticals-gbr-830-a-first-in-class-investigational-anti-ox40-monoclonal-antibody-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-including-an-oral/ 2026-02-24T09:51:18+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-clobetasol-propionate-topical-solution-usp-0-05/ 2026-02-24T09:52:37+00:00 https://glenmarkpharma.com/press_release/glenmark-receives-anda-approval-for-tacrolimus-ointment-0-1/ 2026-02-24T09:53:12+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-initiation-of-a-phase-2b-trial-of-gbr-830-a-first-in-class-investigational-anti-ox40-monoclonal-antibody-for-the-treatment-of-moderate-to-severe-atopic-dermatitis/ 2026-02-24T09:54:01+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-and-helsinn-group-enter-into-an-exclusive-licensing-agreement-for-launch-of-akynzeo-in-india-and-nepal/ 2026-02-24T09:54:56+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-anda-approval-for-clobetasol-propionate-spray-0-05/ 2026-02-24T09:56:06+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-presents-new-data-on-ryaltris-an-investigational-product-for-the-treatment-of-seasonal-allergic-rhinitis-at-the-aaaai-wao-joint-congress/ 2026-02-24T09:56:47+00:00 https://glenmarkpharma.com/press_release/glenmark-launches-a-globally-renowned-hair-growth-formula-nourkrin-woman-in-india/ 2026-02-24T09:58:01+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-enters-exclusive-collaboration-agreement-with-scd-pharmaceuticals-south-korea-for-ophthalmic-solution-products/ 2026-02-24T09:58:35+00:00 https://glenmarkpharma.com/press_release/glenmark-presents-new-data-on-gbr-830-a-first-in-class-investigational-anti-ox40-monoclonal-antibody-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-at-the-2018-american-academy-of-dermat/ 2026-02-24T09:59:14+00:00 https://glenmarkpharma.com/press_release/glenmarks-consolidated-revenue-at-rs-22036-62-mn-for-q3-fy-2017-18/ 2026-02-24T09:59:54+00:00 https://glenmarkpharma.com/press_release/glenmark-presents-preliminary-biomarker-data-on-gbr-1302-a-her2xcd3-bispecific-monoclonal-antibody-at-the-asco-sitc-clinical-immuno-oncology-symposium/ 2026-02-24T10:00:48+00:00 https://glenmarkpharma.com/press_release/glenmark-initiates-phase-iib-dose-range-finding-study-for-novel-molecule-grc-27864/ 2026-02-24T10:01:25+00:00 https://glenmarkpharma.com/press_release/glenmark-launches-the-biosimilar-of-adalimumab-in-india/ 2026-02-24T10:02:13+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-to-launch-sodium-phosphates-injection-usp-15-mm-p-5-ml-45-mm-p-15-ml-and-150-mm-p-50-ml-3-mm-p-ml-single-dose-vials/ 2026-02-27T05:28:27+00:00 https://glenmarkpharma.com/press_release/glenmark-specialty-sa-receives-u-s-fda-approval-for-fluticasone-propionate-inhalation-aerosol-usp-44-mcg-per-actuation-with-180-day-competitive-generic-therapy-exclusivity/ 2026-03-04T05:38:31+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-q3-fy26-results/ 2026-03-07T09:20:55+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-to-launch-potassium-phosphates-injection-usp-15-mmol-p-22-meq-k-per-5-ml-and-45-mmol-p-66-meq-k-per-15-ml-single-dose-vials-and-150-mmol-p-220-meq-k-per-50-ml/ 2026-03-16T06:02:27+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-launches-authorized-generic-to-milnacipran-hydrochloride-tablets-12-5-mg-25-mg-50-mg-and-100-mg/ 2026-03-19T05:53:16+00:00 https://glenmarkpharma.com/press_release/glenmark-therapeutics-inc-usa-launches-fluticasone-propionate-nasal-spray-usp-50-mcg-per-spray-otc/ 2026-03-19T05:58:02+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-launches-glipiq%e2%93%a1-semaglutide-in-india/ 2026-03-20T19:02:23+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-canada-inc-launches-mens-gln-minoxidil-5-w-w-topical-aerosol-foam-in-canadian-retail/ 2026-03-31T13:03:47+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-strategic-shift-to-direct-commercialization-and-distribution-of-ryaltris-in-the-u-s-significantly-expanding-its-innovative-portfolio/ 2026-04-01T12:26:56+00:00 https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-u-s-fda-approval-for-progesterone-vaginal-inserts-100-mg/ 2026-04-09T05:48:53+00:00